Abstract 2766
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is an important factor that renders the continuation of chemotherapy difficult. Prevention and treatment of CIPN are indispensable in improving patients’ quality of life and promoting the continuation of chemotherapy that may improve survival. Numbness and pain are currently evaluated using subjective methods such as the visual analogue scale (VAS). However, the assessment of pain can vary greatly depending on the mood and physical state of the patient at the time of assessment. In this stage, objective evaluation methods have not been used for evaluations of CIPN in clinical trials because they have not been established as quantified evaluation methods for CIPN yet. A method to quantify CIPN objectively and easily is necessary. The PainVision PS-2100 (PV) is an analytical instrument that was designed to quantitatively and objectively assess sense perception and nociception in patients. The advantage of PV is that it can evaluate pain in a relatively short time, as well as assess pain without causing further pain to patients.
Methods
We examined a total of 73 CIPN patients with metastatic CRC received chemotherapy between April 2014 and December 2015 by using VAS, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (NTX), the Disk-Criminator™ test, the monofilament test and PV. And then, we evaluated the correlation between subjective and objective evaluation methods or correlation between PV and other objective evaluation methods for CIPN.
Results
The average VAS (hand), VAS (foot) and PV scores of CIPN were 18.4 (range: 0–100), 23.8 (range: 0–100) and 24.7 (range: 0–496), respectively. A strong positive correlation was found between VAS (hand) and VAS (foot) scores (r = 0.798). The VAS (hand), VAS (foot), NTX 2, NTX 4 and NTX 8 significantly correlated with PV. PV showed no correlation with a Disk-Criminator™ or the monofilament test used as an objective evaluation.
Conclusions
This is the 1st report regarding the correlation between PV and other objective evaluation methods in CIPN patients. The evaluation of CIPN is complicated because numerous factors are involved. And further research and effort are needed to improve objective evaluation of CIPN by PV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract